Evidence map›Paper›PMID 36260403›Full record

ArticleJMIR mHealth and uHealth2021

Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.

Ciao-Sin Chen, Judith Kim, Noemi Garg, Harsha Guntupalli, Reshma Jagsi, Jennifer J Griggs, Michael Sabel, Michael P Dorsch, Brian C Callaghan, Daniel L Hertz

Open access · goldAbstract read
In one paragraph

Article in JMIR mHealth and uHealth, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ciao-Sin ChenDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, United States.ORCID 0000-0002-5917-0958
Judith KimDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, United States.ORCID 0000-0002-7076-9398
Noemi GargDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, United States.ORCID 0000-0002-6443-7020
Harsha GuntupalliDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, United States.ORCID 0000-0002-4621-0172
Reshma JagsiDepartment of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, United States.ORCID 0000-0001-6562-1228
Jennifer J GriggsDepartment of Internal Medicine, Hematology & Oncology Division, University of Michigan Medical School, Ann Arbor, MI, United States.ORCID 0000-0002-1598-4562
Michael SabelDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, United States.ORCID 0000-0001-9215-2914
Michael P DorschDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, United States.ORCID 0000-0003-2910-1879
Brian C CallaghanDepartment of Neurology, University of Michigan Medical School, Ann Arbor, MI, United States.ORCID 0000-0002-8885-6748
Daniel L HertzDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, United States.ORCID 0000-0003-0501-1035
Michigan Medicine · USUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere chemotherapy-induced peripheral neuropathy (CIPN) can cause long-term dysfunction of the hands and feet, interfere with activities of daily living, and diminish the quality of life. Monitoring to identify CIPN and adjust treatment before it progressing to a life-altering severity relies on patients self-reporting subjective symptoms to their clinical team. Objective assessment is not a standard component of CIPN monitoring due to the requirement for specially trained health care professionals and equipment. Smartphone apps have the potential to conveniently collect both subjective and objective CIPN data directly from patients, which could improve CIPN monitoring.

objectiveThe objective of this cross-sectional pilot study was to assess the feasibility of functional CIPN assessment via a smartphone app in patients with cancer that have received neurotoxic chemotherapy.

methodsA total of 26 patients who had completed neurotoxic chemotherapy were enrolled and classified as CIPN cases (n=17) or controls (n=9) based on self-report symptoms. All participants completed CIPN assessments within the NeuroDetect app a single time, including patient-reported surveys (CIPN20 [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Chemotherapy-induced Peripheral Neuropathy 20-item scale] and PRO-CTCAE [Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events]) and functional assessments (Gait and Balance and 9-Hole Peg Test). Functional assessment data were decomposed into features. The primary analysis was done to identify features indicative of the difference between CIPN cases and controls using partial least squares analyses. Exploratory analyses were performed to test if any features were associated with specific symptom subtypes or patient-reported survey scores. Patient interviews were also conducted to understand the challenges they experienced with the app.

resultsComparisons between CIPN cases and controls indicate that CIPN cases had shorter step length (P=.007), unique swaying acceleration patterns during a walking task, and shorter hand moving distance in the dominant hands during a manual dexterity task (variable importance in projection scores ≥2). Exploratory analyses showed similar signatures associated with symptoms subtypes, CIPN20, and PRO-CTCAE. The interview results showed that some patients had difficulties due to technical issues, which indicated a need for additional training or oversight during the initial app download.

conclusionsOur results supported the feasibility of remote CIPN assessment via a smartphone app and suggested that functional assessments may indicate CIPN manifestations in the hands and feet. Additional work is needed to determine which functional assessments are most indicative of CIPN and could be used for CIPN monitoring within clinical care.

Indexed as

Antineoplastic AgentsMobile ApplicationsPeripheral Nervous System DiseasesActivities of Daily LivingCross-Sectional StudiesHumansPilot ProjectsQuality of LifeAntineoplastic Agents9-Hole Peg Testbalancechemotherapy-induced peripheral neuropathygaitmobile healthsmartphone

Identifiers

PMID36260403
PMCPMC8406129
OpenAlexW3155627233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.